anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Levothyroxine (T4) is used to treat patients with hypothyroidism and may often result in lifelong therapy. Its physiologically active metabolite is tri-iodothyronine (T3). Levothyroxine is also endogenously produced in the body. Since small changes in levothyroxine administration (e.g. change in brand or formulation) can cause significant changes in serum thyroid stimulating hormone (TSH) concentrations, precise and accurate TSH control is critical to avoid potential adverse iatrogenic effects. Tecnoquimicas modified its Levothyroxine tablets formulation in order to comply with new pharmacopeical specifications. It will then evaluate the impact on drug product performance based on pharmacokinetic (PK) measures of total serum T4 and total serum T3 of the new formulation of levothyroxine (Test formulation) relative to the reference formulation from Merck (Reference formulation)

This will be a single-center, open-label, two-period, two-treatment, two-sequence, randomized, single-dose, crossover study. 80 healthy adults will be randomized to receive a single dose (4 x 150 mcg tablets = 600 mcg) of the test formulation of levothyroxine and reference formulation of levothyroxine separately in each treatment period. There will be two treatment sequences (AB, BA) and a 42 day washout between the two treatment periods.
The relationship between early spontaneous hypothermia and adverse clinical outcomes in patients with subarachnoid hemorrhage (SAH) has not been paid much attention. We designed this retrospective cohort study to determine this relationship by analyzing the association between the lowest body temperature (T-lowest) on the first day of ICU admission and in-hospital mortality. In this study, 550 participants with non-traumatic SAH were chosen from the Medical Information Mart for Intensive Care (MIMIC)-IV database. Multivariate Cox regression analysis showed that T-lowest was nonlinearity correlated with in-hospital mortality (HR = 0.72, 95% CI: 0.59-0.86, p < 0.001). We divided the T-lowest into quartile groups. In comparison to reference group Q1 (31.30-36.06 ℃), group Q3 (36.56-36.72 ℃) had a 50% lower risk of death in the hospital (HR: 0.5, 95% CI: 0.28-0.87, p = 0.014). We further confirmed the curve-like relationship between T-lowest and in-hospital mortality using restricted cubic splines. The mortality is lowest when the T-lowest is close to 36.5 °C, and the risk of death is increased when the temperature is lower or higher than that. Our study demonstrates that in-hospital mortality is associated with T-lowest. Patients with non-traumatic SAH are at increased risk of death if their body temperature on the first day of ICU admission is too low.
The present invention relates to a process for the isolation of carotenoid crystals having lutein and zeaxanthin in a weight ratio of 10:1, 5:1 and 1:1, respectively. The process comprises contacting a plant source rich in lutein with hexane and extracting at a temperature of 40°C to 60°C to obtain an oleoresin rich in lutein; contacting a plant source rich in zeaxanthin with hexane and extracting at a temperature of 40°C to 60°C to obtain an oleoresin rich in zeaxanthin. The oleoresin rich in lutein and the oleoresin rich in zeaxanthin are mixed separately in a ratios ranging from 80:20(w/w) to 90:10(w/w) or 70:30(w/w) to 30:70(w/w) or 10:90(w/w) to 20:80(w/w), respectively, and homogenized to obtain a mixed oleoresin. The mixed oleoresin is hydrolyzed with an alcoholic alkali at a temperature of 70°C to 80°C to obtain a reaction mixture. The carotenoid crystals are precipitated by adding hot water to the reaction mixture to form a precipitate. Carotenoid crystals having lutein and zeaxanthin in a weight ratio of 10:1 1 or 5:1 or 1: 1, respectively, are obtained by filtering, washing, and drying the precipitate.
Exposure to infectious diseases in early life has been linked to increased mortality risk in later life in high-disease settings, such as eighteenth- and nineteenth-century Europe. Less is known about the long-term effects of early-life disease exposure in milder disease environments. This study estimates heterogeneous effects from disease exposure in infancy on later-life mortality in twentieth-century Sweden, by socioeconomic status at birth and sex. Using historical population data for southern Sweden, we study 11,515 individuals who were born in 1905-1929 from age 1 until age 85. We measure exposure to disease using the local post-early neonatal mortality rate in the first 12 months after birth and apply flexible parametric survival models. For females, we find a negative effect on life expectancy (scarring) at ages 1-85 following high disease exposure in infancy, particularly for those born to unskilled workers. For males, we find no negative effect on later-life survival, likely because stronger mortality selection in infancy outweighs scarring. Thus, even as the incidence of infectious diseases declined at the start of the twentieth century, early-life disease exposure generated long-lasting negative but heterogeneous population health effects.
BACKGROUND: Recent studies have suggested elevated blood eosinophils are independent predictors of response to corticosteroid therapy in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Smoking status has been shown to affect corticosteroid response. Whether the association between high blood eosinophils and corticosteroid treatment failure is modified by smoking has not been fully investigated so far.
OBJECTIVES: This study aimed to assess whether the association between high blood eosinophils and corticosteroid treatment failure is modified by smoking.
METHODS: We included 3402 inpatients with AECOPD treated with corticosteroids at Beijing Chao-Yang Hospital from July 2013 to June 2021. Blood eosinophil counts were measured within 24 hours of admission. An eosinophil percentage ≥2% was considered as high eosinophilic. Smokers in this study were defined as current or former smokers. Treatment failure was defined as a worsening of AECOPD that led to adverse clinical outcomes or required further treatment or an extended hospital stay or hospitalisation following the exacerbation. Multivariate-adjusted logistic models were used to estimate the OR and 95% CI associated with treatment failure.
RESULTS: There were 958 (28.2%) treatment failure events occurring. Patients with high eosinophils had a lower risk of treatment failure (OR 0.74, 95% CI 0.63 to 0.87) than patients with low eosinophils. Compared with never smoking and low eosinophilic group, the ORs for treatment failure were 0.70 (95% CI 0.52 to 0.96) for never smoking and high eosinophilic group, 0.82 (95% CI 0.64 to 1.05) for smoking and low eosinophilic group and 0.62 (95% CI 0.47 to 0.81) for smoking and high eosinophilic group. Furthermore, there was no significant interaction between eosinophils and smoking status in relation to treatment failure (p for interaction=0.73). Similar results were obtained from multiple secondary outcomes and subgroup analyses.
CONCLUSION: Elevated blood eosinophils are associated with a lower rate of corticosteroid treatment failure, regardless of smoking status. Smoking does not modify the association between blood eosinophil level and corticosteroid treatment failure among inpatients with AECOPD.
While hypoxic signaling has been shown to play a role in many cellular processes, its role in metabolism-linked extracellular matrix (ECM) organization and downstream processes of cell fate after musculoskeletal injury remains to be determined. Heterotopic ossification (HO) is a debilitating condition where abnormal bone formation occurs within extra-skeletal tissues. Hypoxia and hypoxia-inducible factor 1α (HIF-1α) activation have been shown to promote HO. However, the underlying molecular mechanisms by which the HIF-1α pathway in mesenchymal progenitor cells (MPCs) contributes to pathologic bone formation remain to be elucidated. Here, we used a proven mouse injury-induced HO model to investigate the role of HIF-1α on aberrant cell fate. Using single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics analyses of the HO site, we found that collagen ECM organization is the most highly up-regulated biological process in MPCs. Zeugopod mesenchymal cell-specific deletion of Hif1α (Hoxa11-CreERT2; Hif1afl/fl) significantly mitigated HO in vivo. ScRNA-seq analysis of these Hoxa11-CreERT2; Hif1afl/fl mice identified the PLOD2/LOX pathway for collagen cross-linking as downstream of the HIF-1α regulation of HO. Importantly, our scRNA-seq data and mechanistic studies further uncovered that glucose metabolism in MPCs is most highly impacted by HIF-1α deletion. From a translational aspect, a pan-LOX inhibitor significantly decreased HO. A newly screened compound revealed that the inhibition of PLOD2 activity in MPCs significantly decreased osteogenic differentiation and glycolytic metabolism. This suggests that the HIF-1α/PLOD2/LOX axis linked to metabolism regulates HO-forming MPC fate. These results suggest that the HIF-1α/PLOD2/LOX pathway represents a promising strategy to mitigate HO formation.
The invention discloses a traditional Chinese medicinal composition for treating epilepsy. The traditional Chinese medicinal composition comprises an effective ingredient which comprises the following components: Coptis chinensis Franch, Bamboo Shavings, Immature bitter orange, radix bupleuri, raw Fossilizid, raw oyster, Curcuma aromatica, and batryticated silkworm, wherein weight percentages of the components are shown in the specification. The traditional Chinese medicinal composition which has the advantages of definite curative effect, less toxic and side effect and no dependency is safe and reliable when the traditional Chinese medicinal composition is taken for a long term. The invention also discloses a preparation method of the traditional Chinese medicinal composition. The preparation method comprises the following steps: 1, weighing the components according to the weight percentages shown in the specification; 2, respectively crushing Curcuma aromatica and batryticated silkworm, sieving, and uniformly mixing for standby; 3, adding water, decocting the rest six traditional Chinese medicines twice, mixing two filtrates to obtain a filtrate, concentrating the filtrate into a clear paste, drying the clear paste at a low temperature, crushing into fine powder, and sieving for standby; and 4, fully mixing a powdery substance obtained in step 3, and preparing a required preparation according to a routine preparation method. The preparation method of the present invention has the advantages of simple step, easy enforcement, and stable technology.
This invention relates to a medical composition comprising therapeutic effective amount of ferric citrate in medical grade and medical acceptable carrier, excipient or diluent, in which the empirical formula of ferric citrate is FeC6H5O7. 3.5H2O. This invention also relates to a method for preparing medical grade ferric citrate by using solid-solid reaction comprising: mixing solid citric acid and solid ferric salt, or adding alcohol into the mixture and filtrating and obtaining solid ferric citrate. This invention also relates to a medical grade ferric citrate, which is homogeneous in quality and comprises an empirical formula FeC6H5O7. 3.5H2O. This invention further relates to a diet nutriment comprising medical grade ferric citrate thereof.
Large volumes of sitting time have been associated with multiple health risks such as diabetes, heart disease and premature death. Especially, in office workers sitting time per day can accumulate to over 10 hours a day. To reduce sitting time for office workers in a Dutch insurance company, an intervention will be implemented. The intervention contains the introduction of alternative workstations, intervention sessions with an occupational physiotherapist and an activity tracker with a self-help program booklet. The goal of this study is to evaluate the (cost) effectiveness of this intervention on the short term (3 months) and long-term (12 months). The primary outcome is objectively assessed sitting time.

In a cluster randomized controlled trial 250 employees of an insurance company will participate in the study. After baseline measurements, matched departments will be randomly assigned to the control or intervention group. The evaluation includes an economic and process evaluation.
PURPOSE:The titled hair tonic that is obtained by adding a fraction soluble in a medium polar organic solvent from KANZO (glycyrriza glabra L.) as an active ingredient. CONSTITUTION:KANZO, a herb, is extracted with methanol or ethanol or their mixture and the extract is shaken together with a medium polar organic solvent-water system, then the organic phase is separated, or the herb is extracted with a medium polar organic solvent such as ethyl acetate or chloroform and the extract is shaken together with water and nonpolar organic solvent such as n-hexane, petroleum ether or benzene to remove fractions soluble in water and nopolar organic solvent to collect the fraction of KANZO soluble in medium polar organic solvent. The fraction is added by 0.1-10.0wt% to give the objective hair tonic for medical purposes. The formulations are preferably in tonic, lotion, cream, aqueous alcohol solution. As cosmetic ingredients to be admixed, pantothenates, vitamin B6, hexachlorophene, etc. are mentioned and as a solvent, distilled water, ethyl alcohol or liquid paraffin is used.
PURPOSE: Radiotherapy (RT) is the primary treatment for prostate cancer (PCa); however, the emergence of castration-resistant prostate cancer (CRPC) often leads to treatment failure and cancer-related deaths. In this study, we aimed to explore the use of microwave hyperthermia (MW-HT) to sensitize PCa to RT and investigate the underlying molecular mechanisms.
METHODS: We developed a dedicated MW-HT heating setup, created an in vitro and in vivo MW-HT + RT treatment model for CRPC. We evaluated PC3 cell proliferation using CCK-8, colony experiments, DAPI staining, comet assay and ROS detection method. We also monitored nude mouse models of PCa during treatment, measured tumor weight, and calculated the tumor inhibition rate. Western blotting was used to detect DNA damage repair protein expression in PC3 cells and transplanted tumors.
RESULTS: Compared to control, PC3 cell survival and clone formation rates decreased in RT + MW-HT group, demonstrating significant increase in apoptosis, ROS levels, and DNA damage. Lower tumor volumes and weights were observed in treatment groups. Ki-67 expression level was reduced in all treatment groups, with significant decrease in RT + MW-HT groups. The most significant apoptosis induction was confirmed in RT + MW-HT group by TUNEL staining. Protein expression levels of DNA-PKcs, ATM, ATR, and P53/P21 signaling pathways significantly decreased in RT + MW-HT groups.
CONCLUSION: MW-HT + RT treatment significantly inhibited DNA damage repair by downregulating DNA-PKcs, ATM, ATR, and P53/P21 signaling pathways, leading to increased ROS levels, aggravate DNA damage, apoptosis, and necrosis in PC3 cells, a well-established model of CRPC.
During the first and second phase of the study, subjects assigned to the control group received one tablet of placebo under daily basis, whereas the mirtazapine group received 30 mg of mirtazapine daily. During the third phase, placebo group received same tablet under daily basis, whereas the mirtazapine group received 15 mg of mirtazapine.
Each 5 mL (one teaspoonful) contains: Cyproheptadine Hydrochloride 2 mg.

Inactive Ingredients: Alcohol 5% v/v, anhydrous citric acid, D&C yellow no. 10, edetate disodium, mint flavor, purified water, sodium benzoate,sodium citrate and sucrose.

Cyproheptadine HCl is an antihistaminic and antiserotonergic agent. Cyproheptadine hydrochloride is a white to slightly yellowish, crystalline solid, with a molecular weight of 350.89, which is slightly soluble in water, freely soluble in methanol, sparingly soluble in ethanol, soluble in chloroform and practically insoluble in ether. It is the sesquihydrate of 4-(5H-dibenzo[a,d] cyclohepten-5- ylidene)-1-methylpiperidine hydrochloride. The molecular formula of the anhydrous salt is C21H21N•HCl and the structural formula of the anhydrous salt is:
The adoption of diets that minimize both their environmental impacts and weight excess in children would be a major co-benefit for climate change mitigation. We evaluated the relationship between child diet-related environmental impact and anthropometric characteristics in an Italian birth cohort. The study involved 2127 children of the Piccolipiù birth cohort. At 4 years, their diet in the previous two months was assessed through a questionnaire, from which we derived individual: (i) diet-related daily greenhouse gas emissions (GHGE), (ii) land use (LU), (iii) adherence to the Mediterranean Diet (MD) and (iv) red meat consumption. We related these variables with overweight and obesity, waist circumference, and height at 4 years using regression models adjusted for a priori selected confounders. Diet-related GHGE and LU had a positive weak association with overweight and obesity, with an odds ratio (OR) for the fourth vs. second quartile of 1.30 for both GHGE (95% confidence intervals -CI-: 0.96; 1.77) and LU (95% CI: 0.96-1.76). Both OR estimates increased after adjustment for energy intake. GHGE and LU were not associated with height, with the exception of shorter children in the first quartile. A high vs. low MD adherence was associated with an increase in height Z-score of 0.11 (95% CI 0.01; 0.21). No association was found for red meat consumption. These results suggest that lowering the impact of high environmental impact diets may have, if anything, beneficial effects on child obesity, overweight, and height, with pro-MD patterns playing an important role.
Open label diet and exercise counseling only. Subjects will be instructed to follow a healthy 1200 calorie diet and record any changes in appetite.
FIELD: medicine and food industry. SUBSTANCE: preparation is designed for treating dysbacteriosis and also for dietetic nutrition of adults and children. "Bifilakt" is prepared by thermostatically controlling defatted milk undergoing fermentation process under specified conditions, after which product is kept to achieve acidity. When treating dysbacteriosis, "bifilakt" is administered in the form of 400-600-ml drinks over 25-45-day period and therapeutic clysters according to following strategy: 1.5 l in a single dose, then 10 days with 0.1-0.15 l for each procedure, and finally 1.5 l in single dose. Product is recommended as drug for wide use in gastroenterology, neurology, immunology, and allergology. EFFECT: extended assortment of nutrition-normalization drugs. 2 cl, 4 ex
Subunit modulation of the GABAA receptor chloride channel macromolecular complex is hypothesized to be responsible for sedative, anticonvulsant, anxiolytic, and myorelaxant drug properties. The major modulatory site of the GABAA receptor complex is located on its alpha (α) subunit and is referred to as the benzodiazepine (BZ) or omega (ω) receptor. At least three subtypes of the (ω) receptor have been identified.

Zolpidem, the active moiety of zolpidem tartrate, is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, pyrrolopyrazines, pyrazolopyrimidines or other drugs with known hypnotic properties, it interacts with a GABA-BZ receptor complex and shares some of the pharmacological properties of the benzodiazepines. In contrast to the benzodiazepines, which non-selectively bind to and activate all BZ receptor subtypes, zolpidem in vitro binds the (BZ1) receptor preferentially with a high affinity ratio of the alpha1/alpha5 subunits. The (BZ1) receptor is found primarily on the Lamina IV of the sensorimotor cortical regions, substantia nigra (pars reticulata), cerebellum molecular layer, olfactory bulb, ventral thalamic complex, pons, inferior colliculus, and globus pallidus. This selective binding of zolpidem on the (BZ1) receptor is not absolute, but it may explain the relative absence of myorelaxant and anticonvulsant effects in animal studies as well as the preservation of deep sleep (stages 3 and 4) in human studies of zolpidem at hypnotic doses.
PURPOSE:To eliminate non-specific agglumination or non-specific attachment on cells by fixing an immunoactive material contg. an NH2 group to the fine particles within a specific grain size range by convalent body with a polymer consisting of glycidyl acrylate or glycidyl methacrylate. CONSTITUTION:Particles of a polymer of glycidyl acrylate or glycidyl methacrylate alone or a copolymer of both or, if necessary, a polymer added with a monomer for crosslinking are obtained in desired grain sizes by a precipitation polymn., emulsion polymn., or suspension polymn. method. Such fine particles and an immunoactive material (antigen, antibody, etc.) having an NH2 group are fixed by covalent bonding. The resulted particles fixed with the immunoactive material enable the stable immunoanalysis with high sensitivity without non- specific agglumination or non-specific attachment on cells owing to the protein, etc. in sample, except the component to be detected.
The invention discloses a tumor-targeted aptamer drug conjugate which comprises an aptamer and a drug, wherein the aptamer and the drug are correspondingly connected through a connecting bond. The aptamer is covalently coupled to the drug. And the sulfydryl of the aptamer is correspondingly and covalently coupled with the maleic amide bond of the drug. The aptamer is a thiol-containing aptamer. The end of the aptamer is modified with C18 or F base. The medicine is VC-MMAE. The aptamer drug conjugate is used for targeted therapy of tumors. The aptamer drug conjugate for tumor targeting connects VC-MMAE to the aptamer with a tumor targeting effect, so that tumor targeting is realized, and the toxic and side effects of the drug are reduced.
The invention discloses a marine antibacterial guaifenesin and application thereof in preparing a wound infection prevention and treatment product. By means of site-directed mutagenesis and the like, 273 peptide fragments with more remarkable antibacterial and healing-promoting activities are preferably obtained. The antibacterial and guaifenesin has broad-spectrum antibacterial activity, can rapidly increase membrane permeability to cause bacterial collapse, and can effectively inhibit the growth of gram-negative bacteria such as escherichia coli, pseudomonas aeruginosa, vibrio vulnificus and the like and gram-positive bacteria such as staphylococcus aureus and the like. The antibacterial and callosity-promoting peptide has good biocompatibility, no cytotoxicity, no hemolysis and obvious promotion of cell proliferation and migration. In the aspect of preventing and treating wound infection, the antibacterial and healing promoting peptide can effectively inhibit bacterial growth, lighten the damage of toxin to organisms, obviously reduce the level of proinflammatory factors, accelerate wound surface contraction and improve the wound surface healing speed and the repairing quality. The antibacterial and callosity-promoting peptide has wide application range, can be applied to medicines and medical biological materials, and has very obvious effect of preventing and treating wound infection.